Fraser Gray, Hornet Therapeutics CEO
May 23, 2024 02:00 PM EDTUpdated 03:11 PM
Startups
R&D

UK biotech re­vives for­mer Ky­owa Kirin can­cer drug for Ep­stein-Barr-dri­ven dis­eases

Ayisha Sharma

News Reporter

Hor­net Ther­a­peu­tics is on a mis­sion to pre­vent and treat con­di­tions re­lat­ed to the Ep­stein-Barr virus (EBV) with the help of a drug can­di­date shelved …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

J&J takes 340B fight with fed­er­al gov­ern­ment to court

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times